DE | EN | ES

News / Presse

HAPILA extends production capacity

HAPILA GmbH (HAPILA) has extended its production capabilities by installation of another pilot plant. The new plant has already delivered first outputs of the innovative API BTZ043 used for tuberculosis (TB) treatment.

These initial batches from a five-step chemical synthesis extended by two further purifying crystallization steps will be used to support BTZ043 toxicological studies, commencing soon.

Fast build

Despite delivery and other problems due to COVID-19 restrictions, it took HAPILA only eight months from design to production start. The repurposed pilot plant now features three reactors up to 250 L with thermal equipment and devices for filtering, drying and exhaust treatment, allowing higher amounts of API to be processed within shorter timescales.

The new production facility secures stable support for preclinical and clinical studies carried out by the partners of the BTZ043 project, achieving higher annual quantity outputs and achieving very high specified quality standards.

Anti-TB effectiveness

Tuberculosis is the most common cause of mortality worldwide caused by bacterial infections, accounting for some 1.4 million deaths annually.

BTZ043 is expected to meet global industry need for TB treatments that take effect more quickly and also overcome problems of growing antibiotic resistance among bacterial strains.